Chemotherapy for MS

Preliminary data from Immunex Corp.'s first Phase III trial of Novantrone mitoxantrone in multiple sclerosis highlights continuing interest among practitioners and researchers in applying chemotherapies, which can kill cells or suppress cell functions, to autoimmune disorders, in which certain immune cells attack the patient's own tissues.

One question is whether the side effects of chemotherapy will preclude its use in MS.